CL2018000226A1 - Mezcla de péptidos (divisional solicitud 201601405) - Google Patents

Mezcla de péptidos (divisional solicitud 201601405)

Info

Publication number
CL2018000226A1
CL2018000226A1 CL2018000226A CL2018000226A CL2018000226A1 CL 2018000226 A1 CL2018000226 A1 CL 2018000226A1 CL 2018000226 A CL2018000226 A CL 2018000226A CL 2018000226 A CL2018000226 A CL 2018000226A CL 2018000226 A1 CL2018000226 A1 CL 2018000226A1
Authority
CL
Chile
Prior art keywords
peptide mixture
divisional application
peptides
ras protein
understand
Prior art date
Application number
CL2018000226A
Other languages
English (en)
Inventor
Jon Amund Eriksen
Original Assignee
Targovax Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP13196333 priority Critical
Application filed by Targovax Asa filed Critical Targovax Asa
Publication of CL2018000226A1 publication Critical patent/CL2018000226A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • A61K39/001164GTPases, e.g. Ras, Rho
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82Translation products from oncogenes

Abstract

<p>SE DESCRIBE UNA MEZCLA DE PÉPTIDOS ADECUADA PARA PRODUCIR UNA RESPUESTA INMUNITARIA. COMPRENDE PÉPTIDOS, CADA UNO QUE CORRESPONDE A UN FRAGMENTO DE LA PROTEÍNA RAS. CADA UNO LOS PÉPTIDOS COMPRENDE UNA REGIÓN DE AL MENOS 6 O AL MENOS 8 AMINOÁCIDOS QUE INCLUYE LA POSICIÓN 12 DE LA PROTEÍNA RAS.</p>
CL2018000226A 2013-12-09 2018-01-26 Mezcla de péptidos (divisional solicitud 201601405) CL2018000226A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13196333 2013-12-09

Publications (1)

Publication Number Publication Date
CL2018000226A1 true CL2018000226A1 (es) 2018-06-22

Family

ID=49765823

Family Applications (4)

Application Number Title Priority Date Filing Date
CL2016001405A CL2016001405A1 (es) 2013-12-09 2016-06-08 A peptide mixture
CL2018000238A CL2018000238A1 (es) 2013-12-09 2018-01-26 Mezcla de péptidos (divisional solicitud 201601405)
CL2018000232A CL2018000232A1 (es) 2013-12-09 2018-01-26 Mezcla de péptidos (divisional solicitud 201601405)
CL2018000226A CL2018000226A1 (es) 2013-12-09 2018-01-26 Mezcla de péptidos (divisional solicitud 201601405)

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CL2016001405A CL2016001405A1 (es) 2013-12-09 2016-06-08 A peptide mixture
CL2018000238A CL2018000238A1 (es) 2013-12-09 2018-01-26 Mezcla de péptidos (divisional solicitud 201601405)
CL2018000232A CL2018000232A1 (es) 2013-12-09 2018-01-26 Mezcla de péptidos (divisional solicitud 201601405)

Country Status (24)

Country Link
US (4) US9775892B2 (es)
EP (5) EP3363458A3 (es)
JP (2) JP6781403B2 (es)
KR (1) KR20160097290A (es)
CN (1) CN105980403A (es)
AU (2) AU2014363643B2 (es)
BR (1) BR112016013138A2 (es)
CA (1) CA2933126A1 (es)
CL (4) CL2016001405A1 (es)
CY (1) CY1120578T1 (es)
DK (1) DK3079715T3 (es)
ES (1) ES2682038T3 (es)
HR (1) HRP20181213T1 (es)
HU (1) HUE039840T2 (es)
IL (1) IL246007D0 (es)
LT (1) LT3079715T (es)
MX (1) MX2016007429A (es)
PL (1) PL3079715T3 (es)
PT (1) PT3079715T (es)
RS (1) RS57623B1 (es)
RU (1) RU2016127327A (es)
SG (2) SG11201604644QA (es)
SI (1) SI3079715T1 (es)
WO (1) WO2015086590A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201604644QA (en) 2013-12-09 2016-07-28 Targovax Asa A peptide mixture
DK3140320T3 (en) 2014-05-06 2019-04-15 Targovax Asa PEPTID VACCINE CONTAINING MUTANT RACE PEPTID AND CHEMOTHERAPEUTIC AGENTS
CN110430894A (zh) * 2017-02-01 2019-11-08 莫得纳特斯公司 编码活化致癌基因突变肽的免疫调节治疗性mrna组合物
AU2018288386A1 (en) * 2017-06-22 2020-02-06 New South Wales Health Pathology Adoptive T cell therapy 2
CN112638404A (zh) * 2018-06-19 2021-04-09 百欧恩泰美国公司 新抗原及其用途
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
AU2019324162A1 (en) * 2018-08-22 2021-03-04 Fred Hutchinson Cancer Center Immunotherapy targeting KRAS or Her2 antigens
WO2021009633A1 (en) * 2019-07-12 2021-01-21 Massey University Synthetic chromatin vaccine
WO2021087840A1 (zh) * 2019-11-07 2021-05-14 武汉华大吉诺因生物科技有限公司 肿瘤免疫治疗多肽及其应用
CN113416241B (zh) * 2020-04-09 2022-04-08 北京臻知医学科技有限责任公司 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
KR101164509B1 (ko) 2002-12-16 2012-07-10 글로브이뮨 면역 요법으로서의 효모계 백신
DE602005016112D1 (de) 2005-09-05 2009-10-01 Immatics Biotechnologies Gmbh Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe
US7745128B2 (en) * 2006-03-27 2010-06-29 Globeimmune, Inc. Ras mutation and compositions and methods related thereto
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
SG11201604644QA (en) 2013-12-09 2016-07-28 Targovax Asa A peptide mixture
DK3140320T3 (en) 2014-05-06 2019-04-15 Targovax Asa PEPTID VACCINE CONTAINING MUTANT RACE PEPTID AND CHEMOTHERAPEUTIC AGENTS

Also Published As

Publication number Publication date
LT3079715T (lt) 2018-08-27
WO2015086590A3 (en) 2015-07-30
US20170189515A1 (en) 2017-07-06
MX2016007429A (es) 2016-11-11
RS57623B1 (sr) 2018-11-30
JP2020023525A (ja) 2020-02-13
PT3079715T (pt) 2018-08-02
SI3079715T1 (en) 2018-08-31
DK3079715T3 (en) 2018-09-17
SG10201811172PA (en) 2019-01-30
CL2016001405A1 (es) 2017-03-24
US20170326218A1 (en) 2017-11-16
PL3079715T3 (pl) 2018-11-30
US20180021419A1 (en) 2018-01-25
EP3357505A1 (en) 2018-08-08
KR20160097290A (ko) 2016-08-17
CA2933126A1 (en) 2015-06-18
US9775892B2 (en) 2017-10-03
WO2015086590A2 (en) 2015-06-18
CY1120578T1 (el) 2019-07-10
HUE039840T2 (hu) 2019-02-28
US20160331820A1 (en) 2016-11-17
CN105980403A (zh) 2016-09-28
EP3079715B1 (en) 2018-06-13
EP3363458A3 (en) 2018-11-07
US10335473B2 (en) 2019-07-02
AU2014363643A1 (en) 2016-07-14
AU2014363643B2 (en) 2019-01-03
HRP20181213T1 (hr) 2018-10-19
EP3369432A1 (en) 2018-09-05
AU2019201937A1 (en) 2019-04-11
US10596239B2 (en) 2020-03-24
JP6781403B2 (ja) 2020-11-04
SG11201604644QA (en) 2016-07-28
RU2016127327A (ru) 2018-01-23
US10456457B2 (en) 2019-10-29
ES2682038T3 (es) 2018-09-18
CL2018000238A1 (es) 2018-06-22
EP3363457A1 (en) 2018-08-22
BR112016013138A2 (pt) 2018-01-16
AU2019201937B2 (en) 2020-05-28
JP2017502081A (ja) 2017-01-19
EP3363458A2 (en) 2018-08-22
IL246007D0 (en) 2016-07-31
CL2018000232A1 (es) 2018-06-22
EP3079715A2 (en) 2016-10-19

Similar Documents

Publication Publication Date Title
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
CL2019003657A1 (es) Anticuerpos que se unen específicamente a cd38 útiles para mejorar una respuesta inmune en un paciente. (divisional solicitud 201703275)
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
EA201690333A1 (ru) МОДУЛОКИНЫ НА ОСНОВЕ ДОМЕНА SUSHI IL-15 И IL-15Rα
UY33983A (es) Proteínas de Unión de Tipo Anticuerpo con Región Variable Dual que Tienen Orientación de la Región de Unión con Entrecruzamiento.
CL2017003228A1 (es) Fragmentos mutantes de proteína ras
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
BR112015009924A2 (pt) formulações de proteína imunoglobulina de domínio variável duplo estáveis
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
CU20190058A7 (es) Composiciones de aminoácidos relacionadas con mejoras de la función hepática
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
EA201591931A1 (ru) Композиции оксабициклогептанов и оксабициклогептенов
BR112018075032A2 (pt) proteínas de hemaglutinina do vírus influenza e seus uso
BR112016024494A8 (pt) análogo de peptídeo e seu uso
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
BR112016022844A2 (pt) método para aperfeiçoar a solubilidade de proteínas e peptídeos utilizando-se uma ligação de fragmento fc de imunoglobulinas
BR112015025699A2 (pt) modulação de especificidade de polipeptídeo estruturado
DK3146042T3 (da) Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop
BR112016013157A2 (pt) peptídeos resistentes à protease
UA117493C2 (uk) Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання
CL2019003167A1 (es) Proteínas de unión al antígeno anti-jagged1.
BR112015032388A2 (pt) métodos e composições para as vacinas contra o vírus da dengue
BR112012013581A2 (pt) vacinas de malária baseadas em ferlinas apicomplexas, proteínas semelhante a ferlinas e outras proteínas que contêm o domínio c2
MX2019007924A (es) Vacunas contra la influenza.